Effects of hypnotics on sleep and quality of life in insomnia

Sleep and Quality of Life in Clinical Medicine

Volumn , Issue , 2008, Pages 53-66

  Alford, Chris ^a   Wilson, Sue ^b  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

accidents; behavioural and psychological treatments; Benzodiazepines; improved waking function; newer benzodiazepine receptor agonist (Z drugs); residual effects

Indexed keywords

EID: 84891378466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-343-5_7     Document Type: Chapter

References (184)

1. Bond AJ, Lader MH. Residual effects of hypnotics. Psychopharmacologia 1972;25(2):117-32.
2. Bond AJ, Lader MH. Residual effects of flunitrazepam. Br J Clin Pharmacol 1975;2(2):143-50.
3. Hindmarch I, Parrott AC, Arenillas L. A repeated dose comparison of dichloralphenazone, flunitrazepam and amylobarbitone sodium on some aspects of sleep and early morning behaviour in normal subjects. Br J Clin Pharmacol 1977;4(2): 229-33.
4. Bond AJ, Lader MH. Proceedings: residual effects of a new benzodiazepine: flurazepam. Br J Pharmacol 1972;44(2): 343P-4P.
5. Hindmarch I, Patat A, Stanley N, Paty I, Rigney U. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening. Hum Psychopharmacol 2001;16(2):159-67.
6. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Lack of residual sedation following middle-of-The-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23(1):17-21.
7. Mathias S, Steiger A, Lancel M. The GABA(A) agonist gaboxadol improves the quality of post-nap sleep. Psychopharmacology (Berl) 2001;157(3):299-304.
8. Walsh JK, Zammit G, Schweitzer PK, Ondrasik J, Roth T. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006;7(2):155-61.
9. National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28(9):1049-57.
10. Thase ME. Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry 2005;27(2):100-12.
11. Bartholini G. Growing aspects of Hypnotic Drugs. In: Sauvanet JP, Langer SZ, Morselli PI, eds. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. New York: Raven Press; 1988. pp. 1-9.
12. Zorick F. Overview of Insomnia. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia, PA: Saunders; 1994. pp. 483-85.
13. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. Manifestations and management of chronic insomnia in adults. Evid Rep Technol Assess (Summ ) 2005;125:1-10.
14. Miller EH. Women and insomnia. Clin Cornerstone 2004;6(Suppl 1B):S8-18.
15. Krystal AD. Depression and insomnia in women. Clin Cornerstone 2004;6(Suppl 1B):S19-28.
16. Asplund R. Sleep disorders in the elderly. Drugs Aging 1999;14(2):91-103.
17. Frighetto L, Marra C, Bandali S, Wilbur K, Naumann T, Jewesson P. An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. Health Qual Life Outcomes 2004;2:17.
18. Ring D. Management of chronic insomnia in the elderly. Clin Excell Nurse Pract 2001;5(1):13-6.
19. Bastien CH, Fortier-Brochu E, Rioux I, LeBlanc M, Daley M, Morin CM. Cognitive performance and sleep quality in the elderly suffering from chronic insomnia. Relationship between objective and subjective measures. J Psychosom Res 2003;54(1):39-49.
20. Morgan K, Clarke D. Longitudinal trends in late-life insomnia: implications for prescribing. Age Ageing 1997;26(3): 179-84.
21. Ohayon MM, Vecchierini MF. Normative sleep data, cognitive function and daily living activities in older adults in the community. Sleep 2005;28(8):981-9.
22. Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 2003;18(4):163-76.
23. Richardson GS, Roth T, Kramer JA. Management of insomnia-The role of zaleplon. Med Gen Med 2002;4(1):9.
24. Roth T. Prevalence, associated risks, and treatment patterns of insomnia. J Clin Psychiatry 2005;66(Suppl 9):10-3.
25. Nishino S, Mignot E. Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations. Clin Pharmacokinet 1999;37(4):305-30.
26. Ohayon MM, Caulet M, Priest RG, Guilleminault C. DSM-IV and ICSD-90 insomnia symptoms and sleep dissatisfaction. Br J Psychiatry 1997;171:382-8.
27. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999;22(Suppl 2):S347-53.
28. Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM. Recommendations for a standard research assessment of insomnia. Sleep 2006;29(9):1155-73.
29. Martin JL, Ancoli-Israel S. Assessment and diagnosis of insomnia in non-pharmacological intervention studies. Sleep Med Rev 2002;6(5):379-406.
30. Byles JE, Mishra GD, Harris MA. The experience of insomnia among older women. Sleep 2005;28(8):972-9.
31. Kageyama T, Kabuto M, Nitta H, Kurokawa Y, Taira K, Suzuki S, Takemoto TI. Prevalence of use of medically prescribed hypnotics among adult Japanese women in urban residential areas. Psychiatry Clin Neurosci 1998;52(1):69-74.
32. Seppala M, Hyyppa MT, Impivaara O, Knuts LR, Sourander L. Subjective quality of sleep and use of hypnotics in an elderly urban population. Aging (Milano) 1997;9(5):327-34.
33. Turski L, Stephens DN, Jensen LH, Petersen EN, Meldrum BS, Patel S, Hansen JB, Loscher W, Schneider HH, Schmiechen R. Anticonvulsant action of the-carboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther 1990;253:344-52.
34. Jensen E, Dehlin O, Hagberg B, Samuelsson G, Svensson T. Medical, psychological, and sociological aspects of drug treatment in 80-year-olds. Z Gerontol 1994;27(2):140-4.
35. Balkrishnan R, Rasu RS, Rajagopalan R. Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States. Sleep 2005;28(6):715-9.
36. Stewart R, Besset A, Bebbington P, Brugha T, Lindesay J, Jenkins R, Singleton N, Meltzer H. Insomnia co-morbidity and impact and hypnotic use by age group in a national survey population aged 16-74 years. Sleep 2006;29(11): 1391-7.
37. Sekine M, Chandola T, Martikainen P, Marmot M, Kagamimori S. Work and family characteristics as determinants of socioeconomic and sex inequalities in sleep: The Japanese Civil Servants Study. Sleep 2006;29(2): 206-16.
38. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc 1992;40(8):787-91.
39. Morgan K. Hypnotic drugs, psychomotor performance and ageing. J Sleep Res 1994;3(1):1-15.
40. Sateia MJ, Nowell PD. Insomnia. Lancet 2004;364(9449): 1959-73.
41. CPMC. Ad hoc group on short-Acting hypnotics. Summary Report for the Committee for Proprietary Medical Products. 1993. Brussels: CPMC. Ref Type: Generic
42. Chevalier H, Los F, Boichut D, Bianchi M, Nutt DJ, Hajak G, Hetta J, Hoffmann G, Crowe C. Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol 1999;13(4 Suppl 1): S21-24.
43. Epstein DR, Bootzin RR. Insomnia. Nurs Clin North Am 2002;37(4):611-31.
44. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003;98(10):1371-8.
45. Rakel RE. Insomnia: concerns of the family physician. J Fam Pract 1993;36(5):551-8.
46. Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 2000;23(2):243-308.
47. Wysowski DK, Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991;151(9):1779-83.
48. Clayton DO, Shen WW. Psychotropic drug-induced sexual function disorders: diagnosis, incidence and management. Drug Saf 1998;19(4):299-312.
49. Hindmarch I, Alford CA, Barwell F, Kerr JS. Measuring the side effects of psychotropics: the behavioural toxicity of antidepressants. J Psychopharmacol 1992;6(2):198-203.
50. Roth T. New trends in insomnia management. J Psychopharmacol 1999;13(4 Suppl 1):S37-40.
51. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6(6):487-95.
52. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22(3):371-5.
53. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. Epidemiology of insomnia, depression, and anxiety. Sleep 2005;28(11):1457-64.
54. Ford DE, Kamerow DB. Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989;262:1479-84.
55. Benca RM. Consequences of insomnia and its therapies. J Clin Psychiatry 2001;62(Suppl 10):33-8.
56. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996;39(6):411-8.
57. Turek FW. Insomnia and depression: if it looks and walks like a duck. Sleep 2005;28(11):1362-3.
58. Kupfer D. Interaction of EEG sleep, antidepressants, and affective disease. J Clin Psychiatry 1982;43(11 Pt 2):30-6.
59. Scharf MB, Hirschowitz J, Zemlan FP, Lichstein M,Woods M. Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. J Clin Psychiatry 1986;47(12): 587-91.
60. Wiegand M, Berger M, Zulley J, von Zerssen D. The effect of trimipramine on sleep in major depressive disorder. Pharmacopsychiatry 1986;19(198):199.
61. Argyropoulos SV, Hicks JA, Nash JR, Bell CJ, Rich AS, Nutt DJ, Wilson SJ. Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res 2003;120(2):179-90.
62. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20(8):533-59.
63. Benedetti F, Pontiggia A, Bernasconi A, Colombo C, Florita M, Smeraldi E. Lormetazepam in depressive insomnia: new evidence of phase-response effects of benzodiazepines. Int Clin Psychopharmacol 2004;19(5):311-7.
64. Idzikowski C. Impact of insomnia on health-related quality of life. Pharmacoeconomics 1996;10(Suppl 1):15-24.
65. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999;22(Suppl 2):S354-8.
66. Leger D. The cost of sleep-related accidents: a report for the national commission on sleep disorders research. Sleep 1994;17(1):84-93.
67. Stoller MK. Economic effects of insomnia. Clin Ther 1994;16(5):873-97.
68. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004;65(Suppl 8):13-9.
69. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics 1996;10(Suppl 1):1-14.
70. Leger D, Massuel MA, Metlaine A. Professional correlates of insomnia. Sleep 2006;29(2):171-8.
71. Godet-Cayre V, Pelletier-Fleury N, Le VM, Dinet J, Massuel MA, Leger D. Insomnia and absenteeism at work. Who pays the cost? Sleep 2006;29(2):179-84.
72. Dinges DF. The state of sleep deprivation: from functional biology to functional consequences. Sleep Med Rev 2006;10(5):303-5.
73. Philip P, Akerstedt T. Transport and industrial safety, how are they affected by sleepiness and sleep restriction? Sleep Med Rev 2006;10(5):347-56.
74. Koski K, Luukinen H, Laippala P, Kivela SL. Risk factors for major injurious falls among the home-dwelling elderly by functional abilities. A prospective population-based study. Gerontology 1998;44(4):232-8.
75. Connor J, Norton R, Ameratunga S, Robinson E, Civil I, Dunn R, Bailey J, Jackson R. Driver sleepiness and risk of serious injury to car occupants: population based case control study. BMJ 2002;324(7346):1125.
76. Johnson LC, Spinweber CL. Good and poor sleepers differ in Navy performance. Mil Med 1983;148(9):727-31.
77. Maclean AW, Davies DR, Thiele K. The hazards and prevention of driving while sleepy. Sleep Med Rev 2003;7(6): 507-21.
78. Stickgold R. Sleep-dependent memory consolidation. Nature 2005;437(7063):1272-8.
79. Curcio G, Ferrara M, De GL. Sleep loss, learning capacity and academic performance. Sleep Med Rev 2006;10(5): 323-37.
80. Wolfson AR, Carskadon MA. Understanding adolescents' sleep patterns and school performance: a critical appraisal. Sleep Med Rev 2003;7(6):491-506.
81. Nissen C, Kloepfer C, Nofzinger EA, Feige B, Voderholzer U, Riemann D. Impaired sleep-related memory consolidation in primary insomnia-A pilot study. Sleep 2006;29(8): 1068-73.
82. Backhaus J, Junghanns K, Born J, Hohaus K, Faasch F, Hohagen F. Impaired declarative memory consolidation during sleep in patients with primary insomnia: influence of sleep architecture and nocturnal cortisol release. Biol Psychiatry 2006;60(12):1324-30.
83. Rombaut N, Maillard F, Kelly F, Hindmarch I. The Quality of Life in Insomniacs questionnaire (QOLI). Med Sci Res 1990;18(845):847.
84. Nutt DJ,Wilson S. Evaluation of severe insomnia in the general population-implications for the management of insomnia: the UK perspective.J Psychopharmacol1999;13(4 Suppl 1):S33-4.
85. Jenkinson C, Coulter A,Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993;306(6890):1437-40.
86. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep 1999;22(Suppl 2):S379-85.
87. Leger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med 2001;63(1):49-55.
88. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154(10):1417-23.
89. Griffiths AN, Tedeschi G, Smith AT, Richens A. The effect of repeated doses of temazepam and nitrazepam on human psychomotor performance. Br J Clini Pharmacol 1983;15:615-6.
90. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology (Berl) 1982;76(2):101-13.
91. Kales A, Bixler EO, Scharf M, Kales JD. Sleep laboratory studies of flurazepam: a model for evaluating hypnotic drugs. Clin Pharmacol Ther 1976;19(5 Pt 1):576-83.
92. Hindmarch I, Ott H, Roth WT. Sleep, Benzodiazepines and Performance: Experimental Methodolgies and Research Prospects. Berlin: Springer-Verlag; 1984.
93. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10(3):189-209.
94. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations -A review. Psychopharmacology (Berl) 1980;71(2):173-9.
95. Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003;33(7):1223-37.
96. Kay D, Blackburn A, Buckingham J, Karacan I. Human pharmacology of sleep. In: Williams R, Karacan I, eds. Pharmacology of Sleep. New York: John Wiley & Sons; 1976.
97. Hartmann E. Longterm administration of psychotropic drugs: effects on human sleep. In: Williams R, Karacan I, eds. Pharmacology of Sleep. New York: John Wiley & Sons; 1976. pp. 211-23.
98. Hindmarch I, Beaumont G, Brandon S, Leonard B. Benzodiazepines: Current Concepts -Biological, Social and Social Perspectives. Chichester: John Wiley & Sons; 1990. pp. 83-210.
99. Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf 1993;9(2):93-103.
100. Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs 1994;1:377-87.
101. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998;10: 425-40.
102. Ohayon MM, Caulet M, Arbus L, Billard M, Coquerel A, Guieu JD, Kullmann B, Loffont F, Lemoine P, Paty J, Pechadre JC, Vecchierini MF, Vespignani H. Are prescribed medications effective in the treatment of insomnia complaints? J Psychosom Res 1999;47(4):359-68.
103. Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee EC. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther 1991;49(4):468-76.
104. Langtry HD, Benfield P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40(2):291-313.
105. Noble S, Langtry HD, Lamb HM. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998;55(2):277-302.
106. Goa KL, Heel RC. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986;32(1):48-65.
107. Walsh J, Fry JM, Erwin CW, Scharf M, Roth T, Vogel G. Efficacy and safety of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Investig 1998;16(347):354.
108. Hajak G, Rodenbeck A. Clinical management of patients with insomnia. The role of zopiclone. Pharmacoeconomics 1996;10(Suppl 1):29-38.
109. Sauvanet JP, Langer SZ, Morselli PIE. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. New York: Raven Press; 1988.
110. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol 2000;15(3):141-52.
111. Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2001;251(3): 117-23.
112. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32(6):680-91.
113. Alford C, Verster J. NICE review: not nice for patients! J Psychopharmacol 2005;19(2):129-32.
114. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, MacDonald TM. Association of road-Traffic accidents with benzodiazepine use. Lancet 1998;352(9137):1331-6.
115. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995;5(3): 239-44.
116. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age Ageing 1996;25(4):273-8.
117. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992;136:873-83.
118. Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000;48(6):682-5.
119. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician 1998;44:799-808.
120. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001;158(6):892-8.
121. Wysowski DK, Baum C, Ferguson WJ, Lundin F, Ng MJ, Hammerstrom T. Sedative-hypnotic drugs and the risk of hip fracture. J Clin Epidemiol 1996;49(1):111-3.
122. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997;278(1):27-31.
123. Subhan Z, Hindmarch I. Assessing residual effects of benzodiazepines on short-Term memory. Pharmaceut Med 1984;1(27):33.
124. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18(5):297-328.
125. Zisapel N, Laudon M. Subjective assessment of the effects of CNS-Active drugs on sleep by the Leeds sleep evaluation questionnaire: a review. Hum Psychopharmacol 2003;18(1):1-20.
126. Puca FM, Perrucci S, Prudenzano MP, Savarese M, Misceo S, Perilli S, Palumbo M, Libro G, Genco S. Quality of life in shift work syndrome. Funct Neurol 1996;11(5):261-8.
127. Stein MB, Barrett-Connor E. Quality of life in older adults receiving medications for anxiety, depression, or insomnia: findings from a community-based study. Am J Geriatr Psychiatry 2002;10(5):568-74.
128. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-Acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004;43(4):227-38.
129. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995;29(3):142-53.
130. Wagner J,Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000;4(6):551-81.
131. Verster J, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta analyses of randomised controlled trials applying the on-The-road driving test. Current Drug Saf 2006;1:63-71.
132. Staner L, Ertle S, Boeijinga P, Rinaudo G, Arnal MA, Muzet A, Luthringer R. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl) 2005;181(4):790-8.
133. Arnedt JT, Wilde GJ, Munt PW, Maclean AW. How do prolonged wakefulness and alcohol compare in the decrements they produce on a simulated driving task? Accid Anal Prev 2001;33(3):337-44.
134. Goldenberg F, Hindmarch I, Joyce CRB, Le Gal M, Partinen M. Zopiclone, sleep and health-related quality of life. Hum Psychopharmacol 1994;9(4):245-51.
135. Leger D, Quera-Salva MA, Philip P. Health-related quality of life in patients with insomnia treated with zopiclone. Pharmacoeconomics 1996;10(Suppl 1):39-44.
136. Scharf M, Erman M, Rosenberg R, Seiden D, McCall WV, Amato D, Wessel TC. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005;28(6):720-7.
137. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006;108(6):1402-10.
138. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the shortterm management of insomnia: a systematic review and metaanalysis. Hum Psychopharmacol 2004;19(5):305-22.
139. Nicholson AN, Stone BM. Imidazobenzodiazepines: sleep and performance studies in humans. J Clin Psychopharmacol 1983;3(2):72-5.
140. Blin O, Micallef J, Audebert C, Legangneux E. A doubleblind, placebo-And flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol 2006;26(3):284-9.
141. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26(7):793-9.
142. Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7(5): 397-406.
143. Jindal RD, Buysse DJ, Thase ME. Maintenance treatment of insomnia: what can we learn from the depression literature? Am J Psychiatry 2004;161(1):19-24.
144. Ohayon MM, Caulet M. Insomnia and psychotropic drug consumption. Prog Neuropsychopharmacol Biol Psychiatry 1995;19(3):421-31.
145. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, III, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-Analysis of treatment efficacy. JAMA 1997;278(24):2170-7.
146. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-Term open study in general practice. J Int Med Res 1992;20(2):162-70.
147. Mendelson WB. Psychophysiological aspects of benzodiazepine treatment for insomnia. Balliere's Clin Psychiatry 1995;1(3):383-9.
148. Mendelson WB. Long-Term follow-up of chronic insomnia. Sleep 1995;18(8):698-701.
149. Monti JM, Monti D, Estevez F, Giusti M. Sleep in patients with chronic primary insomnia during long-Term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996;11(4):255-63.
150. Fleming JA, Bourgouin J, Hamilton P. A sleep laboratory evaluation of the long-Term efficacy of zopiclone. Can J Psychiatry 1988;33(2):103-7.
151. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6(6):487-95.
152. Walsh JK, Vogel GW, Scharf M, Erman M, William EC, Schweitzer PK, Mangano RM, Roth T. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1(1):41-9.
153. Pedrosi B, Roehrs T, Zorick F, Stepanski E, Roth T. Treatment regimen and subsequent self-Administration of benzodiazepine-hypnotics. Sleep Res 1994;23:73.
154. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK,Ware JC. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000;23(8): 1087-96.
155. Hajak G, Cluydts R, Declerck A, Estivill SE, Middleton A, Sonka K, Unden M. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, doubleblind, randomized, outpatient study. Int Clin Psychopharmacol 2002;17(1):9-17.
156. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep 1998;21(2):178-86.
157. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005;28(11):1465-71.
158. Adam K, Oswald I. The hypnotic effects of an antihistamine: promethazine. Br J Clin Pharmacol 1986;22:715-7.
159. Alford CA, Rombaut N, Jones J, Foley S, Idzikowski C, Hindmarch I. Acute effects of hydroxyzine on nocturnal sleep and sleep tendency the following day: a C-EEG study. Hum Psychopharmacol 1992;7:25-37.
160. Risberg AM, Risberg J, Ingvar DH. Effects of promethazine on nocturnal sleep in normal man. Psychopharmacologia 1975;43(3):279-84.
161. Lewy AJ, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol Int 2006;23(1-2): 403-12.
162. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-Analysis. J Gen Intern Med 2005;20(12):1151-8.
163. Wheatley D. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol 2005;19(4):414-21.
164. Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleepdisturbed older adults. Phytother Res 2004;18(10):831-6.
165. Bent S, Padula A, Moore D, Patterson M, MehlingW. Valerian for sleep: a systematic review and meta-Analysis. Am J Med 2006;119(12):1005-12.
166. Goel N, Kim H, Lao RP. An olfactory stimulus modifies nighttime sleep in young men and women. Chronobiol Int 2005;22(5):889-904.
167. Lewith GT, Godfrey AD, Prescott P. A single-blinded, randomized pilot study evaluating the aroma of Lavandula augustifolia as a treatment for mild insomnia. J Altern Complement Med 2005;11(4):631-7.
168. Komori T, Matsumoto T, Yamamoto M, Motomura E, Shrioyama T, Okazaki Y. Application of fragrance in discontinuing the long-Term use of hypnotics. Intl J Aromather 2006;16(1): 3-7.
169. Dixon S, Morgan K, Mathers N, Thompson J, Tomeny M. Impact of cognitive behavior therapy on health-related quality of life among adult hypnotic users with chronic insomnia. Behav Sleep Med 2006;4(2):71-84.
170. Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the management of long-Term hypnotic drug use: a pragmatic randomised controlled trial. Br J Gen Pract 2003;53(497):923-8.
171. Morin CM, Mimeault V, Gagne A. Nonpharmacological treatment of late-life insomnia. J Psychosom Res 1999;46(2): 103-16.
172. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL. Psychological and behavioral treatment of insomnia:update of the recent evidence (1998-2004). Sleep 2006;29(11):1398-414.
173. Kupfer DJ. Pathophysiology and management of insomnia during depression. Ann Clin Psychiatry 1999;11(4):267-76.
174. McCrae CS, Rowe MA, Dautovich ND, Lichstein KL, Durrence HH, Riedel BW, Taylor DJ, Bush AJ. Sleep hygiene practices in two community dwelling samples of older adults. Sleep 2006;29(12):1551-60.
175. Mamelak M, Buck L, Csima A, Price V, Smiley A. Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol-drug interaction. Sleep 1987;10(Suppl 1):79-87.
176. Mamelak M, Csima A, Buck L, Price V. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 1989;9(4):260-7.
177. Monti JM. Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 1989;36(5):461-6.
178. Moskowitz H, Linnoila M, Roehrs T. Psychomotor performance in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990;10(4 Suppl): 44S-55S.
179. Judd LL, Ellinwood E, McAdams LA. Cognitive performance and mood in patients with chronic insomnia during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990;10(4 Suppl):56S-67S. 180. Ponciano E, Freitas F, Camara J, Faria M, Barreto M, Hindmarch I. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin Psychopharmacol 1990;5(Suppl 2):69-77.
180. Nakra BR, Gfeller JD, Hassan R. A double-blind comparison of the effects of temazepam and triazolam on residual, daytime performance in elderly insomniacs. Int Psychogeriatr 1992;4(1):45-53.
181. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55(5): 192-9.
182. Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med 2003;4(6):553-61.
183. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20(12): 1979-91.
184. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7(1): 17-24.